Close Menu

NEW YORK – Fluidigm said on Wednesday that it has completed the acquisition of InstruNor, a privately held, Oslo-based provider of integrated sample preparation systems for flow and mass cytometry.

Fluidigm purchased all outstanding shares of InstruNor for approximately $7.2 million, including $5.2 million in cash and approximately $2 million in stock.

InstruNor will become a part of Fluidigm's mass cytometry business, and Fluidigm said it expects the transaction to be accretive to earnings in 2021.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.